Rigel Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases. The company has a market cap of $209.13 million, a P/E ratio of -2.47 and a beta of 1.54. The company has a quick ratio of 2.08, a current ratio of 2.19 and a debt-to-equity ratio of 4.39. The business has a 50-day simple moving average of $1.39 and a two-hundred day simple moving average of $1.91. Rigel Pharmaceuticals has a 52 week low of $0.64 and a 52 week high of $3.91. Shares of NASDAQ RIGL opened at $1.21 on Thursday. 80.94% of the stock is owned by hedge funds and other institutional investors. Laurion Capital Management LP now owns 2,984,400 shares of the biotechnology company’s stock worth $7,909,000 after acquiring an additional 1,859,400 shares during the last quarter. Finally, Laurion Capital Management LP grew its position in Rigel Pharmaceuticals by 165.3% during the 4th quarter. LLC now owns 4,409,833 shares of the biotechnology company’s stock worth $13,185,000 after acquiring an additional 77,225 shares during the last quarter. LLC grew its position in Rigel Pharmaceuticals by 1.8% during the 1st quarter. Rock Springs Capital Management LP now owns 4,921,487 shares of the biotechnology company’s stock worth $14,715,000 after acquiring an additional 61,287 shares during the last quarter. Rock Springs Capital Management LP grew its position in Rigel Pharmaceuticals by 1.3% during the 1st quarter. now owns 9,132,210 shares of the biotechnology company’s stock worth $27,305,000 after acquiring an additional 104,096 shares during the last quarter.
grew its position in Rigel Pharmaceuticals by 1.2% during the 1st quarter. State Street Corp now owns 23,945,568 shares of the biotechnology company’s stock worth $27,058,000 after acquiring an additional 16,421,362 shares during the last quarter. State Street Corp grew its position in Rigel Pharmaceuticals by 218.2% during the 2nd quarter. Hedge Funds Weigh In On Rigel PharmaceuticalsĪ number of large investors have recently modified their holdings of RIGL. Riley lowered their price target on Rigel Pharmaceuticals from $4.00 to $1.25 and set a “neutral” rating on the stock in a report on Thursday, June 9th. HC Wainwright raised their price target on Rigel Pharmaceuticals from $7.00 to $15.00 and gave the company a “buy” rating in a report on Thursday, August 18th. Piper Sandler raised their price target on Rigel Pharmaceuticals from $1.00 to $2.00 and gave the company a “neutral” rating in a report on Tuesday, August 16th. Cantor Fitzgerald cut Rigel Pharmaceuticals from an “overweight” rating to a “neutral” rating and lowered their price target for the company from $6.00 to $1.00 in a report on Wednesday, June 8th. Jefferies Financial Group cut Rigel Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, June 8th. Several analysts have weighed in on the company. The average 1 year price objective among brokerages that have covered the stock in the last year is $3.96. Five investment analysts have rated the stock with a hold recommendation and one has assigned a buy recommendation to the company. ( NASDAQ:RIGL – Get Rating) have earned an average rating of “Hold” from the nine ratings firms that are presently covering the firm, reports.
0 kommentar(er)
